Note: NK cell activation reagent

Background

OK432 is a freeze-dried, devitalized preparation of a low-virulence strain (Su strain) of Streptococcus pyogenes inactivated by penicillin. It was originally developed in Japan and has been widely used in cancer immunotherapy and the treatment of certain benign diseases.

Specifications

Activity	NK cells activated with this product have a cytotoxic index (T-C) of at least 15%
Formulation	Lyophilized
Stability & Storage	Samples are stable for up to 24 months from date of receipt at 4 ℃. Recommend to aliquot OK432 into smaller quantities for optimal storage. Avoid repeated freeze-thaw cycles.

Immunomodulatory Effects of OK432

Neutrophil Activation: OK432-activated neutrophils can kill IFN-γ or TNF-α-treated cancer cells. It induces neutrophil-mediated cytotoxicity against autologous tumor cells through CD11b/CD18 and ICAM-1 binding.
Monocyte-Mediated Tumor Killing: OK432-activated monocytes exhibit cytotoxic effects against autologous tumor cells, contributing to an anti-tumor immune response.
NK Cell Activation: OK432 enhances NK cell activity by stimulating monocytes/macrophages to secrete IL-12, leading to NK cell-mediated tumor cytotoxicity.
LAK (Lymphokine-Activated Killer) Cell Activity: After stimulation by OK432, lymphocytes exhibit potent LAK cell activity, even capable of targeting anti-NK tumor cells.
Dendritic Cell Maturation: It upregulates the expression of co-stimulatory molecules (CD80/CD86), enhancing antigen presentation efficiency.
Cytokine Release and Th1 Immune Response: OK432 significantly increases IFN-γ, TNF-α, and IL-6 secretion, driving Th1 polarization and strengthening anti-tumor immunity.
Tumor Microenvironment Remodeling: OK432 suppresses regulatory T cell (Treg) activity and promotes tumor-associated macrophage (TAM) polarization to an anti-tumor M1 phenotype.

Direct Anti-Tumor Effects of OK432

Tumor Cell Apoptosis Induction: OK432 activates the TLR4/MyD88 pathway, triggering caspase cascade-induced apoptosis in tumor cells.
Anti-Angiogenesis: Suppresses VEGF expression, limiting tumor blood vessel formation and restricting tumor growth.
Epigenetic Regulation: Downregulates DNA methyltransferase (DNMT) activity, reversing tumor suppressor gene silencing, such as p16.

With its multifaceted immunomodulatory and direct anti-tumor effects, OK432 is widely used in cancer immunotherapy, offering a promising approach to enhancing immune system responses against tumors.

References

Sakamoto N1,2, Ishikawa T3,4, Kokura S5,6, Okayama T7,8, Oka K9, Ideno M10, Sakai F11, Kato A12, Tanabe M13, Enoki T14, Mineno J15, Naito Y16, Itoh Y17, Yoshikawa T18.
Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J Transl Med. 2015 Aug 25;13:277. doi: 10.1186/s12967-015-0632-8.
Pan K1, Lv L2, Zheng HX1, Zhao JJ1, Pan QZ1, Li JJ1, Weng DS1, Wang DD1, Jiang SS1, Chang AE3, Li Q3, Xia JC1. OK-432 synergizes with IFN-γ to confer dendritic cells with enhanced antitumor immunity. Immunol Cell Biol. 2014 Mar;92(3):263-74. doi: 10.1038/icb.2013.87. Epub 2013 Dec 3.
Sudo T1, Aruga A, Shimizu K, Matsushita N, Takasaki K. OK432-activated natural killer cells enhanced trastuzumab (Herceptin)-mediated antibody-dependent cellular cytotoxicity in patients with advanced cancer. Anticancer Res. 2006 Nov-Dec;26(6B):4327-33.

Document

NK Cell Activator-OK432-T&L

NK Cell Activator-OK432-T&L_SDS